rheumatoid arthritis or plaque psoriasis
Rheumatology · 2016–2018
2decisions
1medicine
2carried consumer input
3individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| methotrexate Severe active rheumatoid arthritis or severe psoriasis when oral methotrexate is unsuitable. For psoriasis, the condition must not have adequately responded to… | Jul 2018 | Recommended with restriction | 3 individuals |
| methotrexate Treatment of rheumatoid arthritis or psoriasis when methotrexate oral tablet is unsuitable. | Mar 2016 | Not recommended | input received |
What the PBS pays
$20M in government benefit over 2024–25, across 445,602 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| methotrexate | $19.9M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.